

**Table 5: Cisplatin-based chemotherapy regimen currently in use for the treatment of malignant germ cell tumors and sex cord stromal tumors (from Schneider et al, 2012)**

<b>Drug</b>	<b>Doses</b>	<b>No of cycles</b>
<b>U.S. Childrens Oncology Group: PEb (9048/8891;9049/8890) [26]</b>		
Cisplatin	20 mg/m <sup>2</sup> , day 1,2,3,4,5 or: 33 mg/m <sup>2</sup> , day 1,2,3	3 to 4 cycles
Etoposide	100 mg/m <sup>2</sup> , day 1,2,3,4,5 or: 167 mg/m <sup>2</sup> , day 1,2,3	
Bleomycin	15 U/m <sup>2</sup> , day 1	
<b>German MAKEI Study Group: PE and PEI (MAKEI 96) [20]</b>		
Cisplatin	20 mg/m <sup>2</sup> , day 1,2,3,4,5	2 to 4 cycles
Etoposide	100 mg/m <sup>2</sup> , day 1,2,3	
Ifosfamide	1500 mg/m <sup>2</sup> , day 1,2,3,4,5	
<b>French GCT Study Group; VIP (TGM 1995) [8]</b>		
Cisplatin	20 mg/m <sup>2</sup> , day 1,2,3,4,5	High risk and CSCT, up to 4 cycles
Etoposide	75 mg/m <sup>2</sup> , day 1,2,3,4,5	
Ifosfamide	3000 mg/m <sup>2</sup> , day 1,2	
<b>Italian GCT study group (PEb) [15]</b>		
Cisplatin	25 mg/m <sup>2</sup> , day 1,2,3,4	up to 4 cycles
Etoposide	100mg/m <sup>2</sup> , day 1,2,3,4	
Bleomycin	15 U/m <sup>2</sup> , day 2,	